Ali J Marian

List of Publications by Year in Descending Order

177 papers	11,383 citations	57 h-index	104 g-index
221 ext. papers	13,306 ext. citations	9.6 avg, IF	6.59 L-index

#	Paper	IF	Citations
177	Haploinsufficiency of Tmem43 in cardiac myocytes activates the DNA damage response pathway leading to a late-onset senescence-associated pro-fibrotic cardiomyopathy. *Cardiovascular Research* , **2021**, 117, 2377-2394	9.9	9
176	Clinical Significance of Variants in the Gene in a Large Cohort of Patients With Sporadic Dilated Cardiomyopathy. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 657689	5.4	2
175	Molecular Genetic Basis of Hypertrophic Cardiomyopathy. *Circulation Research*, **2021**, 128, 1533-1553	15.7	15
174	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. *Cardiovascular Research*, **2021**,	9.9	2
173	Single-Cell RNA Sequencing Uncovers Paracrine Functions of the Epicardial-Derived Cells in Arrhythmogenic Cardiomyopathy. *Circulation*, **2021**, 143, 2169-2187	16.7	5
172	Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography. *Acta Pharmacologica Sinica*, **2021**, 42, 1567-1574	8	11
171	Highlights of American Heart Association Scientific Sessions 2020: a virtual experience. *Cardiovascular Research*, **2021**, 117, e10-e12	9.9	
170	FAT10 protects against ischemia-induced ventricular arrhythmia by decreasing Nedd4-2/Nav1.5 complex formation. *Cell Death and Disease*, **2021**, 12, 25	9.8	3
169	Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. *Cardiovascular Pathology*, **2021**, 50, 107278	3.8	22
168	Clinical Interpretation and Management of Genetic Variants. *JACC Basic To Translational Science*, **2020**, 5, 1029-1042	8.7	9
167	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovascular Research*, **2020**, 116, 1666-1687	9.9	714
166	Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies. *Cardiovascular Research*, **2020**, 116, 1600-1619	9.9	15
165	BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/C-deficient mice. *Journal of Clinical Investigation*, **2020**, 130, 4740-4758	15.9	12
164	Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. *Journal of the American College of Cardiology*, **2020**, 75, 2649-2660	15.1	58
163	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. *International Journal of Cardiology*, **2020**, 302, 124-130	3.2	10
162	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2020**, 396, 759-769	40	149
161	Identification of Genes and Pathways Regulated by Lamin A in Heart. *Journal of the American Heart Association*, **2020**, 9, e015690	6	3

160	Heart Failure as a Consequence of Hypertrophic Cardiomyopathy **2020**, 311-321.e6		
159	Exercise restores dysregulated gene expression in a mouse model of arrhythmogenic cardiomyopathy. *Cardiovascular Research*, **2020**, 116, 1199-1213	9.9	18
158	DNA Damage Response/TP53 Pathway Is Activated and Contributes to the Pathogenesis of Dilated Cardiomyopathy Associated With LMNA (Lamin A/C) Mutations. *Circulation Research*, **2019**, 124, 856-873	15.7	48
157	Genomic Reorganization of Lamin-Associated Domains in Cardiac Myocytes Is Associated With Differential Gene Expression and DNA Methylation in Human Dilated Cardiomyopathy. *Circulation Research*, **2019**, 124, 1198-1213	15.7	37
156	Efficacy of Nifekalant in Patients With Wolff-Parkinson-White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings. *Journal of the American Heart Association*, **2019**, 8, e012511	6	5
155	Knock Down of Plakophillin 2 Dysregulates Adhesion Pathway through Upregulation of miR200b and Alters the Mechanical Properties in Cardiac Cells. *Cells*, **2019**, 8,	7.9	7
154	A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. *Human Gene Therapy*, **2018**, 29, 927-937	4.8	4
153	Suppression of Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of Laminopathies. *Circulation Research*, **2018**, 122, 678-692	15.7	27
152	Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study. *Circulation Research*, **2018**, 122, 1109-1118	15.7	28
151	Genetic Testing in Cardiovascular Medicine. *Texas Heart Institute Journal*, **2018**, 45, 231-232	0.8	1
150	Scientists on the Spot: A brief word with Ali J. Marian on cardiovascular genetics. *Cardiovascular Research*, **2018**, 114, e91-e92	9.9	
149	A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy: A Classic Single-Gene Disorder. *Circulation Research*, **2017**, 120, 1084-1090	15.7	29
148	New landscape of cardiovascular genetics and genomics. *Current Opinion in Cardiology*, **2017**, 32, 229-231	2.1	
147	Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome. *JACC Basic To Translational Science*, **2017**, 2, 122-131	8.7	1
146	Distinct Cellular Basis for Early Cardiac Arrhythmias, the Cardinal Manifestation of Arrhythmogenic Cardiomyopathy, and the Skin Phenotype of Cardiocutaneous Syndromes. *Circulation Research*, **2017**, 121, 1346-1359	15.7	15
145	Non-syndromic cardiac progeria in a patient with the rare pathogenic p.Asp300Asn variant in the LMNA gene. *BMC Medical Genetics*, **2017**, 18, 116	2.1	4
144	Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. *Circulation Research*, **2017**, 121, 749-770	15.7	417
143	Identification of established arrhythmogenic right ventricular cardiomyopathy mutation in a patient with the contrasting phenotype of hypertrophic cardiomyopathy. *BMC Medical Genetics*, **2017**, 18, 24	2.1	5

142	Knockdown of Plakophilin 2 Downregulates miR-184 Through CpG Hypermethylation and Suppression of the E2F1 Pathway and Leads to Enhanced Adipogenesis In Vitro. *Circulation Research*, **2016**, 119, 731-50	15.7	35
141	The Case of "Missing Causal Genes" and the Practice of Medicine: A Sherlock Holmes Approach of Deductive Reasoning. *Circulation Research*, **2016**, 119, 21-4	15.7	10
140	Clinical applications of molecular genetic discoveries. *Translational Research*, **2016**, 168, 6-14	11	4
139	Genetics and Genomics of Single-Gene Cardiovascular Diseases: Common Hereditary Cardiomyopathies as Prototypes of Single-Gene Disorders. *Journal of the American College of Cardiology*, **2016**, 68, 2831-2849	15.1	31
138	Cardiac Fibro-Adipocyte Progenitors Express Desmosome Proteins and Preferentially Differentiate to Adipocytes Upon Deletion of the Desmoplakin Gene. *Circulation Research*, **2016**, 119, 41-54	15.7	57
137	Cardiovascular Genetics: Focus on Genetics of Coronary Artery Disease. *Cardiovascular Medicine*, **2015**, 727-735	0.1	1
136	Arrhythmogenic cardiomyopathy in a patient with a rare loss-of-function KCNQ1 mutation. *Journal of the American Heart Association*, **2015**, 4, e001526	6	18
135	A rare loss-of-function SCN5A variant is associated with lidocaine-induced ventricular fibrillation. *Pharmacogenomics Journal*, **2014**, 14, 372-5	3.5	6
134	Framework for development of physician competencies in genomic medicine: report of the Competencies Working Group of the Inter-Society Coordinating Committee for Physician Education in Genomics. *Genetics in Medicine*, **2014**, 16, 804-9	8.1	95
133	Recent developments in cardiovascular genetics and genomics. *Circulation Research*, **2014**, 115, e11-7	15.7	5
132	Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 306, H547-56	5.2	14
131	The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. *Circulation Research*, **2014**, 114, 454-68	15.7	171
130	Sequencing your genome: what does it mean?. *Methodist DeBakey Cardiovascular Journal*, **2014**, 10, 3-6	2.1	16
129	Causality in genetics: the gradient of genetic effects and back to Koch's postulates of causality. *Circulation Research*, **2014**, 114, e18-21	15.7	22
128	Ali J. Marian: life and science are one. *Circulation Research*, **2014**, 115, 549-51	15.7	
127	Recent developments in cardiovascular stem cells. *Circulation Research*, **2014**, 115, e71-8	15.7	25
126	Genomics in cardiovascular disease. *Journal of the American College of Cardiology*, **2013**, 61, 2029-37	15.1	24
125	The discovery of the ACE2 gene. *Circulation Research*, **2013**, 112, 1307-9	15.7	15

124	FAT10 protects cardiac myocytes against apoptosis. *Journal of Molecular and Cellular Cardiology*, **2013**, 59, 1-10	5.8	28
123	Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. *Cardiovascular Research*, **2013**, 97, 44-54	9.9	32
122	Noncoding RNAs in cardiovascular biology and disease. *Circulation Research*, **2013**, 113, e115-20	15.7	12
121	Molecular genetic studies of complex phenotypes. *Translational Research*, **2012**, 159, 64-79	11	104
120	Challenges in medical applications of whole exome/genome sequencing discoveries. *Trends in Cardiovascular Medicine*, **2012**, 22, 219-23	6.9	30
119	The enigma of genetics etiology of atherosclerosis in the post-GWAS era. *Current Atherosclerosis Reports*, **2012**, 14, 295-9	6	22
118	Molecular, cellular, and functional characterization of myocardial regions in hypertrophic cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2012**, 5, 419-22	3.9	7
117	Elements of "missing heritability". *Current Opinion in Cardiology*, **2012**, 27, 197-201	2.1	40
116	Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. *Circulation Research*, **2012**, 111, 907-19	15.7	98
115	Heart Failure as a Consequence of Restrictive Cardiomyopathy **2011**, 395-407		
114	Medical DNA sequencing. *Current Opinion in Cardiology*, **2011**, 26, 175-80	2.1	9
113	Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. *European Journal of Clinical Investigation*, **2011**, 41, 527-38	4.6	59
112	Determinants of plasma vitamin D levels in patients with acute coronary syndromes. *European Journal of Clinical Investigation*, **2011**, 41, 1299-309	4.6	6
111	Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. *Journal of Thrombosis and Thrombolysis*, **2011**, 31, 146-53	5.1	7
110	Molecular genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy: a disease of cardiac stem cells. *Pediatric Cardiology*, **2011**, 32, 360-5	2.1	36
109	Genome-wide association studies complemented with mechanistic biological studies identify sortilin 1 as a novel regulator of cholesterol trafficking. *Current Atherosclerosis Reports*, **2011**, 13, 190-2	6	5
108	Strategic approaches to unraveling genetic causes of cardiovascular diseases. *Circulation Research*, **2011**, 108, 1252-69	15.7	68
107	Molecular genetic and functional characterization implicate muscle-restricted coiled-coil gene (MURC) as a causal gene for familial dilated cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2011**, 4, 349-58		39

106	Mitochondrial genetics and human systemic hypertension. *Circulation Research*, **2011**, 108, 784-6	15.7	19
105	Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy. *Circulation Research*, **2011**, 109, 1342-53	15.7	111
104	Modeling human disease phenotype in model organisms: "It's only a model!". *Circulation Research*, **2011**, 109, 356-9	15.7	17
103	Hypertrophic cardiomyopathy: from genetics to treatment. *European Journal of Clinical Investigation*, **2010**, 40, 360-9	4.6	83
102	Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. *European Journal of Clinical Investigation*, **2010**, 40, 976-83	4.6	30
101	Arrhythmogenic right ventricular cardiomyopathy is a disease of cardiac stem cells. *Current Opinion in Cardiology*, **2010**, 25, 222-8	2.1	27
100	The personal genome and the practice of cardiovascular medicine. *Methodist DeBakey Cardiovascular Journal*, **2010**, 6, 13-20	2.1	2
99	PCSK9 as a therapeutic target in atherosclerosis. *Current Atherosclerosis Reports*, **2010**, 12, 151-4	6	10
98	Update on hypertrophic cardiomyopathy. *Texas Heart Institute Journal*, **2010**, 37, 322-3	0.8	2
97	Nature's genetic gradients and the clinical phenotype. *Circulation: Cardiovascular Genetics*, **2009**, 2, 537-9		26
96	Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. *Circulation*, **2009**, 119, 1398-407	16.7	88
95	Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. *Circulation Research*, **2009**, 104, 1076-84	15.7	118
94	The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. *BMC Cardiovascular Disorders*, **2009**, 9, 3	2.3	31
93	Cytochrome p-450 polymorphisms and response to clopidogrel. *Current Atherosclerosis Reports*, **2009**, 11, 157-60	6	3
92	Experimental therapies in hypertrophic cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2009**, 2, 483-92	3.3	28
91	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. *BMC Medical Genetics*, **2009**, 10, 111	2.1	37
90	Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. *American Journal of Human Genetics*, **2009**, 84, 617-27	11	364
89	Contemporary treatment of hypertrophic cardiomyopathy. *Texas Heart Institute Journal*, **2009**, 36, 194-204	0.8	30

88	Identifying modifier loci in existing genome scan data. *Annals of Human Genetics*, **2008**, 72, 670-5	2.2	10
87	Utilities and limitations of genetic testing for hypertropic cardiomyopathy. *Expert Opinion on Medical Diagnostics*, **2008**, 2, 539-46		2
86	Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. *Cardiovascular Research*, **2008**, 79, 109-17	9.9	48
85	Genetic determinants of cardiac hypertrophy. *Current Opinion in Cardiology*, **2008**, 23, 199-205	2.1	67
84	Genetic Testing For Hypertrophic Cardiomyopathy. *Methodist DeBakey Cardiovascular Journal*, **2008** , 4, 17-20	2.1	
83	Genome-wide association study of susceptibility alleles for coronary artery disease. *Current Atherosclerosis Reports*, **2008**, 10, 183-5	6	
82	Clinical implications of the "personal" genome. *Current Atherosclerosis Reports*, **2008**, 10, 361-3	6	3
81	The genetic basis of cardiomyopathy. *Current Cardiovascular Risk Reports*, **2008**, 2, 468-475	0.9	
80	Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated with an increased upper limit of vulnerability in a transgenic rabbit model of human hypertrophic cardiomyopathy. *Circulation Research*, **2007**, 101, 1049-57	15.7	50
79	Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. *Circulation Research*, **2007**, 100, 766-8	15.7	145
78	MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. *Human Molecular Genetics*, **2007**, 16, 2453-62	5.6	210
77	Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. *Human Molecular Genetics*, **2007**, 16, 2463-71	5.6	61
76	Cardiac Hypertrophy **2007**, 1177-1188		
75	Clinical significance of single nucleotide polymorphisms in PCSK9. *Current Atherosclerosis Reports*, **2007**, 9, 175-6	6	
74	Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. *Journal of the American College of Cardiology*, **2006**, 47, 827-34	15.1	92
73	Beta-adrenergic receptors signaling and heart failure in mice, rabbits and humans. *Journal of Molecular and Cellular Cardiology*, **2006**, 41, 11-3	5.8	20
72	Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. *Journal of Clinical Investigation*, **2006**, 116, 2012-21	15.9	419
71	Interleukin-18 and cardiovascular events. *Current Atherosclerosis Reports*, **2006**, 8, 173-4	6	

70	Recent advances in genetics and treatment of hypertrophic cardiomyopathy. *Future Cardiology*, **2005**, 1, 341-53	1.3	3
69	A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. *Journal of the American College of Cardiology*, **2005**, 45, 1611-9	15.1	122
68	Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. *Circulation Research*, **2005**, 97, 285-92	15.7	120
67	Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. *Circulation*, **2005**, 111, 21-9	16.7	120
66	Regulatable atrial natriuretic peptide gene therapy for hypertension. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13789-94	11.5	47
65	On mice, rabbits, and human heart failure. *Circulation*, **2005**, 111, 2276-9	16.7	21
64	Pharmacogenetic study of statin therapy and cholesterol reduction. *Current Atherosclerosis Reports*, **2005**, 7, 177-8	6	
63	Statins and the Modulation of Cardiac Hypertrophy and Fibrosis: Implications in the Therapy of Heart Failure **2004**, 143-162		1
62	Biomarkers of cardiac disease. *Expert Review of Molecular Diagnostics*, **2004**, 4, 805-20	3.8	21
61	Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. *Circulation*, **2004**, 109, 1284-91	16.7	198
60	Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. *Journal of the American College of Cardiology*, **2004**, 44, 2221-30	15.1	22
59	Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2004**, 36, 663-73	5.8	38
58	Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. *American Heart Journal*, **2004**, 148, 269-76	4.9	7
57	Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. *Circulation*, **2003**, 108, 395-8	16.7	195
56	On predictors of sudden cardiac death in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2003**, 41, 994-6	15.1	19
55	Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 2748-53	11.5	202
54	To screen or not is not the question--it is when and how to screen. *Circulation*, **2003**, 107, 2171-4	16.7	19
53	Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. *Journal of Molecular Medicine*, **2002**, 80, 737-44	5.5	39

52	On Koch's postulates, causality and genetics of cardiomyopathies. *Journal of Molecular and Cellular Cardiology*, **2002**, 34, 971-4	5.8	5
51	Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region. *Blood*, **2001**, 97, 3306-7	2.2	34
50	Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. *Circulation*, **2001**, 104, 317-324	16.7	95
49	Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. *Circulation*, **2001**, 104, 317-24	16.7	282
48	Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. *Circulation Research*, **2001**, 88, 969-73	15.7	96
47	On genetics of dilated cardiomyopathy and transgenic models: all is not crystal clear in myopathic hearts. *Circulation Research*, **2001**, 89, 3-5	15.7	4
46	Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. *Circulation*, **2001**, 103, 789-91	16.7	301
45	On genetics, inflammation, and abdominal aortic aneurysm: can single nucleotide polymorphisms predict the outcome?. *Circulation*, **2001**, 103, 2222-4	16.7	26
44	Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. *Circulation*, **2001**, 104, 128-30	16.7	470
43	A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. *Atherosclerosis*, **2001**, 154, 633-40	3.1	50
42	Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. *Journal of the American College of Cardiology*, **2001**, 38, 1175-80	15.1	118
41	The molecular genetic basis for hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 655-70	5.8	330
40	Molecular Pathophysiology of Cardiomyopathies **2001**, 1045-1063		
39	A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. *Journal of Molecular Medicine*, **2000**, 78, 562-8	5.5	26
38	Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. *Circulation*, **2000**, 102, 1346-50	16.7	144
37	A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. *Circulation Research*, **2000**, 86, 391-5	15.7	118
36	Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q(92), responsible for human hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2000**, 32, 365-74	5.8	19
35	Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. *Journal of the American College of Cardiology*, **2000**, 35, 89-95	15.1	71

34	Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. *Lancet, The*, **2000**, 355, 58-60	40	180
33	Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2000**, 32, 2369-77	5.8	61
32	Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. *Journal of the American College of Cardiology*, **2000**, 36, 1572-8	15.1	83
31	Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. *Atherosclerosis*, **1999**, 144, 435-42	3.1	32
30	Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. *Stroke*, **1999**, 30, 969-73	6.7	109
29	A transgenic rabbit model for human hypertrophic cardiomyopathy. *Journal of Clinical Investigation*, **1999**, 104, 1683-92	15.9	136
28	In vivo short-term expression of a hypertrophic cardiomyopathy mutation in adult rabbit myocardium: myofibrillar incorporation without early disarray. *Proceedings of the Association of American Physicians*, **1999**, 111, 45-56		5
27	Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. *Journal of Cardiovascular Electrophysiology*, **1998**, 9, 88-99	2.7	80
26	Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. *Journal of Clinical Investigation*, **1998**, 102, 1498-505	15.9	89
25	Genetic markers: genes Involved in atherosclerosis. *European Journal of Cardiovascular Prevention and Rehabilitation*, **1997**, 4, 333-339		7
24	Genetic markers: genes involved in human hypertension. *European Journal of Cardiovascular Prevention and Rehabilitation*, **1997**, 4, 341-345		4
23	A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. *Atherosclerosis*, **1997**, 128, 107-12	3.1	80
22	1.P.312 Homocyst(e)ine level but not MTHFR genotype predicts carotid atherosclerosis. *Atherosclerosis*, **1997**, 134, 82-83	3.1	2
21	Identification of a genetic locus for familial atrial fibrillation. *New England Journal of Medicine*, **1997** , 336, 905-11	59.2	449
20	Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. *Journal of the American College of Cardiology*, **1997**, 29, 1468-73	15.1	25
19	Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. *Circulation Research*, **1997**, 81, 76-85	15.7	64
18	Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. *New England Journal of Medicine*, **1996**, 335, 1071-2; author reply 1073-4	59.2	62
17	Molecular genetics of hypertrophic cardiomyopathy. *Journal of Cardiac Failure*, **1996**, 2, S87-95	3.3	3

16	Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. *Clinical Cardiology*, **1995**, 18, 189-98	3.3	23
15	Molecular genetics of hypertrophic cardiomyopathy. *Annual Review of Medicine*, **1995**, 46, 213-22	17.4	19
14	Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations. *European Heart Journal*, **1995**, 16, 368-76	9.5	93
13	Molecular approaches for screening of genetic diseases. *Chest*, **1995**, 108, 255-65	5.3	4
12	Apolipoprotein epsilon 4 is not a genetic risk factor for coronary artery disease or restenosis after percutaneous transluminal coronary angioplasty. *American Journal of Cardiology*, **1995**, 75, 1181-3	3	15
11	Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. *Circulation*, **1995**, 92, 3387-9	16.7	95
10	Recent advances in the molecular genetics of hypertrophic cardiomyopathy. *Circulation*, **1995**, 92, 1336-47	16.7	128
9	Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. *Circulation*, **1995**, 92, 1808-12	16.7	141
8	Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. *Circulation Research*, **1995**, 77, 98-106	15.7	46
7	A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. *Journal of Clinical Investigation*, **1995**, 96, 3005-8	15.9	258
6	Molecular Analysis of Genotype/Phenotype Correlations of Hypertrophic Cardiomyopathy. *Developments in Cardiovascular Medicine*, **1995**, 3-19		1
5	Inadvertent administration of rtPA to a patient with type 1 aortic dissection and subsequent cardiac tamponade. *American Journal of Emergency Medicine*, **1993**, 11, 613-5	2.9	18
4	Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. *Lancet, The*, **1993**, 342, 1085-6	40	329
3	Expression of a missense mutation in the messenger RNA for beta-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy. *Journal of Clinical Investigation*, **1992**, 90, 271-7	15.9	43
2	Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. *Journal of Clinical Investigation*, **1992**, 90, 2156-65	15.9	65
1	Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB. *Circulation*, **1990**, 82, 759-64	16.7	144